Analyst Reco. GSK plc

Equities

Real-time Estimate Cboe Europe Other stock markets 04:46:36 2025-07-09 EDT			5-day change	1st Jan Change
1,411.25 ^GBX	-0.19%		-0.14%	+4.75%

03:58am	Europe rises despite new US tariff mayhem	AN
07-08	Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	MT

GSK : UBS reiterates its Neutral rating	07-03	ZD
AlphaValue/Baader Europe Upgrades GSK to Buy, Trims PT	07-01	MT
GSK : UBS reaffirms its Neutral rating	07-01	ZD
GSK : Gets a Neutral rating from Goldman Sachs	06-30	ZD
GSK : JP Morgan reiterates its Sell rating	06-30	ZD
Sadif Investment Analytics Downgrades GSK to Hold, Cuts PT	06-13	MT
GSK : JP Morgan remains a Sell rating	06-10	ZD
GSK : Bernstein keeps its Buy rating	06-04	ZD
Berenberg Downgrades GSK to Hold From Buy, Keeps $41 Price Target	06-03	MT
GSK : Berenberg lowers his opinion and switches to Neutral	06-03	ZD
GSK PLC : Despite its challenges, GSK remains investable	05-21
GSK : Berenberg reiterates its Buy rating	05-16	ZD
GSK : JP Morgan remains a Sell rating	05-14	ZD
GSK : Deutsche Bank reiterates its Neutral rating	05-14	ZD
GSK : Goldman Sachs reiterates its Neutral rating	05-14	ZD
GSK : Deutsche Bank reaffirms its Neutral rating	05-12	ZD
GSK : Sell rating from JP Morgan	05-01	ZD
GSK : Goldman Sachs remains Neutral	05-01	ZD
GSK : JP Morgan reiterates its Sell rating	05-01	ZD
GSK : UBS gives a Neutral rating	05-01	ZD
GSK PLC : A healthy start to 2025; guidance unchanged	04-30
GSK : UBS remains Neutral	04-30	ZD
GSK : Jefferies remains Neutral	04-30	ZD
GSK : Oddo BHF still neutral	04-30	CF
GSK : JP Morgan maintains a Sell rating	04-30	ZD

No results for this search

GSK PLC : Despite its challenges, GSK remains investable

May 21, 2025 at 10:08 am

GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

GSK plc : Back on track

May 03, 2024 at 05:17 am